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exit tunnel modulation as 
resistance mechanism of S. aureus 
erythromycin resistant mutant
Yehuda Halfon1, Donna Matzov1, Zohar eyal  1, Anat Bashan  1, ella Zimmerman1, 
Jette Kjeldgaard2, Hanne ingmer3 & Ada Yonath1
the clinical use of the antibiotic erythromycin (ery) is hampered owing to the spread of resistance genes 
that are mostly mutating rRnA around the ery binding site at the entrance to the protein exit tunnel. 
Additional effective resistance mechanisms include deletion or insertion mutations in ribosomal protein 
uL22, which lead to alterations of the exit tunnel shape, located 16 Å away from the drug’s binding 
site. We determined the cryo-eM structures of the Staphylococcus aureus 70S ribosome, and its ery 
bound complex with a two amino acid deletion mutation in its ß hairpin loop, which grants the bacteria 
resistance to ery. the structures reveal that, although the binding of ery is stable, the movement of 
the flexible shorter uL22 loop towards the tunnel wall creates a wider path for nascent proteins, thus 
enabling bypass of the barrier formed by the drug. Moreover, upon drug binding, the tunnel widens 
further.
Several ribosomal antibiotics inhibit protein biosynthesis by targeting functional sites in the ribosome, including 
the decoding center, the peptidyl transferase center (PTC) and the ribosomal exit tunnel (NPET) in which the 
nascent proteins migrate until they emerge out of the ribosome. The NPET, which is lined mostly by the 23S 
ribosomal RNA (rRNA) chain, initiates near the PTC and transverses through the large ribosomal subunit (LSU). 
Four ribosomal proteins (rProteins), uL4, uL22, uL23 and uL24, of which the globular regions are located on the 
ribosome surface, extend to line the tunnel walls. Loops of uL4 and uL22 that form the tunnel narrowest con-
striction close to the tunnel entrance whereas uL23 and uL24, are part of the tunnel exit (Fig. 1). Previous studies 
showed that the tunnel interactions with specific sequence motifs of the nascent protein, which may lead to gene 
expression regulation due to translation arrest1–13.
Erythromycin (ery), the first macrolide antibiotic that was introduced clinically14, is composed of a 
14-member macrolactone ring to which two sugar moieties, desosamine and cladinose are attached. It binds 
to the ribosome NPET wall at about 5–7 peptide bonds distance from the PTC (Fig. 1)15 and blocks part of the 
NPET, thus preventing the progretion of nascent peptide chains. It has been shown that for macrolides, the most 
common resistance mechanisms are by A2058G mutation (E. coli numbering is used throughout) at the antibiotic 
binding site or by the erm encoded methylase that methylates the exocyclic nitrogen of the adenine base16–20.
An additional resistance mechanism to ery was reported over 40 years ago in E. coli where a strain with three 
amino acids Met82-Lys-Arg deletion in uL22 showed high affinity to ery binding but was not inhibited by it21–24. 
Other bacteria and archaea, such as H. marismortui, S. pneumoniae, S. aureus, S. pyogenes, H. pylori, H. influenza, 
F. tularensis and D. radiodurans also exhibited similar behavior upon mutation in uL2225–32. The mutations in 
uL22 including insertions, deletions and single amino acid substitutions are mostly located on the ß hairpin 
loop of uL22, which extends from the globular domain of the protein and reaches the tunnel wall. Many of such 
mutated ribosomes maintain high affinity ery binding along with resistance to it2,3,22,24.
S. aureus (SA) is a gram-positive pathogen that is a major cause of infections acquired in hospitals and in 
the community, particularly if the cutaneous barrier has been damaged3. Many hospital-acquired infections are 
caused by highly resistant bacteria such as methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. 
aureus (VRSA)33–35 where both methicillin and vancomycin are targeting the cell wall rather than the ribosome. 
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The high-resolution structures of the ribosome from S. aureus as well as of its complexes with a few clinically 
useful drugs and new potential inhibitors were determined in our lab36 and shed light on its explicit drug inhibi-
tion properties and selectivity as well as on its specific structural elements to be targeted. Directed evolution can 
be used for identifying and isolating mutated bacteria that show resistance to antibiotics and is a helpful tool for 
identifying new resistance mechanisms, which may lead to a better understanding of species-specific resistance 
mechanisms. It was applied for the isolation a uL22 mutant S. aureus ribosome (SAuL22m) from a wild type strain 
of S. aureus, which harbors a 2 amino acid deletion in the ß hairpin loop of uL2226.
We present here the single particle cryo-EM high resolution structures of the apo and ery bound SAuL22m 
mutant ribosome, which demonstrates how deletion of R88-A89 in S. aureus ribosomal protein uL22 ß hairpin 
loop leads to ery resistance although it does not hamper the binding of the antibiotic itself. We also show that 
upon ery binding additional conformational changes occur that are beyond the expected changes, occur as a 
result of the deletion per se. In addition, by comparing the current structures with the native SA ribosome and 
additional uL22 mutants structures from other bacterial species17,25,26, we highlight the specific structural changes 
that occurred in each of the uL22 mutant proteins which nevertheless led to a similar outcome at the cellular level.
Results and Discussion
The single particle cryo-EM structures of the 70S ribosomes from apo uL22 mutant S. aureus (SAuL22m_apo) 
and of its complex with ery (SAuL22m_ery) were determined at 3.58 Å and 3.2 Å, respectively (Table S1). A 
focused refinement of both large subunits resulted in a 2.4 Å and 2.3 Å cryo-EM reconstructed maps, respectively. 
These maps allowed for the unambiguous assignment of ery within SAuL22m_ery complex structure (Fig. 2A) 
and for defining the interactions of ery with the rRNA nucleotides at the binding site (Fig. 2B) including the iden-
tification of the nucleotides that bind ery via hydrophobic interactions as well as its hydrogen bonds (Fig. 2C). Ery 
inhibition assays using SA_WT and SAuL22m ribosomes clearly show that the mutant ribosomes are resistant to 
ery (Fig. S1).
The cryo-EM maps allowed for the unambiguous tracing of the uL22 hairpin loop of both SAuL22m_apo and 
its complex structure with ery (Fig. 3A). Upon superposition of the SA50S wild type (PDBID 6HMA, SA50S_
WT) and the SAuL22m_apo structures, we identified conformational changes of uL22 that are due to the deletion 
mutation that shifts the beta hairpin loop by 6A from its location in the wild type. Consequently, next to the uL22 
ß hairpin loop the rRNA nucleotides A1614 (located in H59a tip) is rotated about 45° (Fig. 4A) and H35 is dis-
placed by about ~3.0 Å (Fig. 4B).
In addition, we identified several conformational changes at the macrolide’s binding site of nucleotides A2062, 
A2439, G2505, U2585, G2583 and A2602. A small movement of A-site nucleotides and helix H92 was also 
detected. Some of these changes are significant, namely, A2439 shifts about 3 Å and U2585 is about 45° rotated 
(Fig. 4C). Nucleotides G2505 and C2610 are rotated by about 45° and 90° respectively (Fig. 5C).
By the superposition of the SAuL22m_ery complex structure on the two apo structures above we could iden-
tify several conformational changes that occurred upon ery binding; At the binding site, A2062 is 45° rotated, 
U2585 is 110° rotated, G2505 is 90° and U2506 is about 3.5 Å shifted in order to accomodate G2505 and forms a 
hydrogen bond with it (Fig. 4C). A small rotation of about 20° of nucleotide G2610 was also identified (Fig. 5C).
Interestingly, upon ery binding, G2505 is about 30° rotated towards C2610, which is 45° rotated, to form a 
WC base pair (BP) with it, where this movement seems to be at the final step in the mid-way movement shown 
in SAuL22m_apo relative to SA50S_WT. A similar BP was also identified in the structures of E. coli and T. 
thermophilus complexes with ery (PDBID 4V7U, EC70S and PDBID 4V7X, respectively); however, in both D. 
Figure 1. The ribosome nascent chain tunnel environment Left: The 70S S. aureus (SA_WT) ribosome where 
the large subunit is shown in light grey and the small subunit is shown in dark grey (PDBID 5TCU). The 
A-site, P-site and E-site docked tRNA molecules (from PDBID 5JTE) are shown in blue, green and magenta, 
respectively. The surface of a nascent chain within the tunnel is shown in yellow. Erythromycin surface is shown 
in red, uL4, uL22, uL23 and uL24 are shown in brown, orange, teal and khaki, respectively. Right: zoom into the 
ery binding site at the upper tunnel.
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radiodurans uL22 mutant apo and ery bound structures (PDBID 4WFN and 4U67, respectively) no such move-
ment has been identified. This movement stabilizes ery binding to the mutant by providing additional hydropho-
bic interaction (Fig. 5C).
Figure 2. The binding pocket of erythromycin within SAL22m_ery structure. (A) Ery 3D structure as modeled 
in the cryo-EM map of the SAL22m_ery complex structure. The map is contoured around the ligand at 3σ. (B) 
Ery binding site in the SAuL22m_ery complex structure at the large subunit. Among the rRNA nucleotides that 
form the ery binding pocket, marked is the hydrogen bond between A2058 and ery (numbering according to E. 
coli with S. aureus numbering in parentheses). (C) Ery interactome within its binding pocket at the SAuL22m_ery 
ribosome. Ery maintains a dense array of electrostatic interactions with rRNA residues within the binding pocket 
at the LSU. rRNA nucleotides are numbered according to the E. coli numbering. Hydrogen bonds and hydrophobic 
interactions are presented as green and red dashed lines. Bond lengths are presented in ångström (Å).
Figure 3. Conformational changes in the mutant upon erythromycin binding. (A) uL22 ß hairpin loop tip 
modeled into the cryo-EM map of SAuL22m_apo (coral) and of SAuL22m_ery (grey). (B) The cascade of 
movements of rRNA and rProteins that occur upon ery binding to the mutant ribosome.
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By inspecting the structural changes that occur upon ery binding to the mutant ribosome we could identify a 
cascade of movements (Fig. 3B). At the ery binding site, nucleotide G2505 rotates almost 90°, forms a new base 
pair with C2610 and is stabilized by another bond with U2506. U746 moves together with H35 by about ~3.0 Å 
to form a bond with OP1 of C2611. Then, A1614 rotates by about 45o where this rotation is stabilized by a bond 
between N6 from A789 and OP2 of A1614. Due to such cascade of events uL22 ß hairpin loop shifts to the tunnel 
wall.
By comparison of uL22 ß hairpin loop of the SA50S_WT, SAuL22m_apo and SAuL22m_ery structures, 
we found that the loop is shifted towards the center of the tunnel in the SAuL22m_apo structure whereas in 
SAuL22m_ery complex structure it is shifted back closer to its location in SA50S_WT structure (Fig. 4A). 
Nevertheless, the tip of the beta hairpin loop moves towards the tunnel wall and a new cavity that adds to the 
tunnel width forms (Figs 5B and S4).
These findings, combined with binding assays that showed no changes in the binding affinity of ery to native 
SA ribosome compared to the mutant ribosome26, are in line with the clear electron density of ery. Thus, it sup-
ports the idea that the uL22 mutation does not dramatically affect ery binding site, but provides an alternative 
mechanism for nascent proteins progression through the NPET.
Previous studies suggested that nascent proteins can bypass the ery in the ribosome by stabilizing A2062 in 
a conformation that increases the space available for their passage37. We add to this proposed stabilization of 
A2062, the deletion mutation at the tip of the ß hairpin loop that forms an additional free space in the tunnel 
through which the nascent proteins can bypass the antibiotic (Fig. 5). By comparing the uL22 hairpin region 
among SA50S_WT, EC70S (PDBID 4V7U) and SAuL22m_apo, a new groove was identified. Upon ery binding, 
an additional groove form in SAuL22m_ery structure. Thus, we suggest that the uL22m new groove widens the 
tunnel in which the nascent protein can pass and bypass ery’s steric blockage (Fig. S4). This mechanism, which is 
activated upon drug binding, is a new finding that suggests a rearrangement of the tunnel further to the expected 
changes due to the deletion mutation. It also supports the necessity to study the complex SAuL22m_ery structure.
Sequence alignment of other, similar, uL22 ery resistant mutant ribosomes from the archaea H. marismortui 
and the eubacteria D. radiodurans, indicates that the mutations occur in proximity to conserved positions around 
the tip of the beta hairpin loop (Fig. 5A) and the specific mutated nucleotides in the SAuL22m are highly con-
served among bacteria. Our studies explain why changes in this region of uL22 are crucial for the destabilization 
of its loop and the development of the antibiotic’s resistance. Comparative structural studies of the various uL22 
mutants’ ribosomes reveal different conformations of the loop. The structure of H. marismortui uL22m_del3 with 
Figure 4. Comparison of uL22 ß hairpin loop and ery binding pocket in SA50S_WT vs. SAuL22m_apo and 
SAuL22m_ery. (A) Overlay of uL22 ß hairpin loop tip of SA50S_WT, SAuL22m_apo and SAuL22m_ery 
structures in blue, coral and grey, respectively. Nucleotide A1614 undergoes the largest movement within uL22 
ß hairpin loop conformational changes. (B) H35 conformational changes upon mutation near uL22 ß hairpin 
loop; Overlay of SA50S_WT and SAuL22m_apo structures (blue and coral, SAuL22m_ery complex structure is 
not shown since it overlaps very well with SAuL22m_ery structure at this region) display a shift in H35 towards 
the uL22 loop new position in the mutant. (C) Overlay of SA50S_WT, SAuL22m_apo and SAuL22m_ery 
structures in blue, coral and grey, respectively, showing the ery binding pocket region, highlighting the rRNA 
nucleotides undergo conformational changes.
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no bound antibiotics (PDBID 1YJ9) shows that a three amino acids deletion further downstream of the ß hairpin 
loop leads to a change of the loop conformation from the tunnel wall which leads to a widening of the tunnel 
(Fig. 5B). The structure of a three amino acids insertion in D. radiodurans in complex with ery (PDBID 4WFN) 
displays a widening of the uL22 tip itself and reveals a small movement of the loop towards the tunnel wall 
(Fig. 5B). The importance of residue 90 of uL22, which is not conserved among bacterial species, for erythromy-
cin resistance was recently reported38. This finding further supports our results since the deletion is in proximity 
to Q90 and changes its location.
A recent study reported that a Vibiro export monitoring polypeptide (VemP) acts as a cis-regulatory poly-
peptide and interacts with R92 and R95 of uL22 in order to stall the ribosome13. Upon superposition of VemP of 
E. coli (PDBID 5NWY) on SA50S_WT, SAuL22m_apo and SAuL22m_ery we observed that while in S. aureus 
uL22 residue 95 is alanine instead of arginine the overall structure remains the same in SA50S_WT. However, 
in mutant SAuL22m_apo there is a vast opening in proximity to the ß hairpin loop and the new groove lead to a 
more spacious tunnel for peptides movement through the tunnel. Upon ery binding to the mutant, in SAuL22m_
ery structure, additional grooves are formed, which leads to a wider tunnel (Fig. 6). We suggest that this change 
affects resistance to ery while potentially preserving the stalling function of the cis-regulatory polypeptides, which 
are important to the normal function of the bacteria. A recent computational study39 suggests that erythromy-
cin slows or stalls synthesis of ErmCL compared to H-NS due to stronger interactions with particular residue 
positions along the nascent protein. uL22 various mutations may change the rate of stalling of specific protein 
synthesis while ery is bound at the NPET and changes the electrostatic and dispersion interactions with nascent 
proteins.
Our results confirm that diverse mutations in the rProtein uL22 ß hairpin loop occur in various bacterial 
species and, by applying slightly different mechanisms, they facilitate nascent protein progression in the exit 
Figure 5. Comparative analysis of the uL22 ß hairpin loop and ery stabilization. (A) Sequence alignment of 
uL22 ß hairpin loop region (residues 69–107) from S. aureus, D. radiodurans and H. marismortui and their 
mutant counterparts. The sites of the deletions in the mutants are marked in red squares and the insertion site 
is marked by a green square. Residue 90 is marked by a purple box. (B) The superposition of uL22 ß hairpin 
loop from SA50S_WT (PDBID 5NGM blue), SAuL22m_apo (coral), SAuL22m_Ery (grey), DRuL22_3ins 
(PDBID 4WFN, green) and HMuL22_3del (PDBID 1YJ9, magenta) structures. Ery structure is shown in red. 
SAuL22m_apo loop has a similar conformation to the SA50S_WT (with a shorter loop due to deletion) while 
in SAuL22m_Ery complex structure the uL22 tip points away from the tunnel wall. (C) Upon ery binding to 
SAuL22m (grey), a new WC base pair, which stabilizes ery binding, is formed between rRNA nucleotides G2505 
(2532) and C2610 (2637). An overlay of SA50S_WT (blue), SAuL22m_apo (coral), E70S (PDBID 4V7U, pink), 
D50S (PDBID 4WFN, green). The conformational changes of rRNA nucleotides C2610 and G2505 are shown. 
Between SA50S_WT (blue) and the mutant apo in SAuL22m_apo structure (coral), a movement of about ~45o 
and ~90o respectively is observed. Upon ery binding, the movement proceeds by ~35o and ~90o in SAuL22m_
ery (grey) to form the WC base pairing. A similar BP has been observed in E70S (PDBID 4V7U) (pink) and 
in T70S (PDBID 4V7X). However, in D. radiodurans uL22 mutant (D50SL22m) no such movement has been 
observed (green).
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tunnel. All are overcoming the erythromycin binding at the upper tunnel wall, resulting in a seemingly common, 
however somewhat different, resistance mechanism against the drug at the bacterial level.
Materials and Methods
Ribosome purification. The bacteria were isolated and grown as described26,36. The bacteria were lysed 
enzymatically using lysostaphin (50 mg/ml) in 10 mM Hepes pH = 7.6, 30 mM MgCl2, 150 mM NH4Cl, 6 mM ß 
-mercaptoethanol for 45 minutes at 37 °C. The lysate was then centrifuged for 45 minutes at 20,000 rpm in Ti-70 
rotor. The supernatant was layered on 1.1 M of sucrose cushion and centrifuge for 20 hours at 40,000 rpm in Ti-70 
rotor. The supernatant was discarded, and the pellet was dissolved in 10 mM Hepes pH = 7.6, 14 mM MgCl2, 
100 mM NH4Cl, 50 mM KCl, 6 mM ß -mercaptoethanol buffer. The 70 S ribosomes were purified by sucrose gra-
dient ultracentrifugation, on a gradient of 10–50% sucrose in the same buffer for 17.5 hours at 18,000 rpm in 
SW-28 rotor. The samples were kept in 10 mM Hepes pH = 7.6, 10 mM MgCl2, 60 mM NH4Cl 15 mM KCl buffer 
and brought to a final concentration not exceeding 1,000 A260 mL−1, and then flash-frozen in liquid nitrogen 
and stored at −80 °C.
Ribosomal inhibition assay. The inhibition assay was performed in 160 mM Hepes-KOH (pH 7.5), 6.5% 
PEG 8 K, 0.074 mg/ml tyrosine, 1.3 mM ATP, 0.86 mM CTP, GTP and UTP, 208 mM potassium glutamate, 83 mM 
creatine phosphate, 28 mM NH4OAc, 0.663 mM cAMP, 1.8 mM DTT, 0.036 mg/ml folinic acid, 0.174 mg/ml 
E.coli tRNA mix, 1 mM amino acid, 8 μM Mg(OAc)2, 0.25 mg/ml creatine kinase, 0.027 mg/ml T7 RNA polymer-
ase 0.003 μg/μl luciferase plasmid and E.coli S100 lysate (which doesn’t include ribosomes) and added 300 nM of 
the ribosomes. A concentration range of erythromycin was 140μM-0.01 μM in 1:2 serial dilutions. The results 
were plotted and IC50 values were calculated using the program GraFit 7. IC50 values were determined by fitting 
the inhibition data to a four-parameters IC50 equation: = 
+ ( )
range
1 x
IC
s
50
 where Range is the maximum y range, and s 
is a slope factor. The x axis represents the concentration of the analyte. Data fitted to this equation are usually 
displayed with a logarithmically scaled x axis. The visualization of the data is obtained using GraFit software40.
complex preparation. The SAuL22mery was peppered by incubating 23 μl of the 0.3 mg/ml ribosome in 
10 mM Hepes pH = 7.6, 10 mM MgCl2, 60 mM NH4Cl 15 mM KCl buffer for 30 minutes at 26 °C, then 1.1 μl of 
10 mM ery dissolved in 10% Ethanol was added and the mixture was incubated for 20 minutes on ice.
eM Sample preparation. Both samples were flash frozen using VitrobotTM VI (FEI) using the following 
conditions: For the SAuL22m_apo grids a ribosome concentration of 1 mg/ml was used on QUANTIFOIL® R 
1.2/1.3. while for SAuL22M_ery grids, a ribosome concentration of 0.3 mg/ml was used on QUANTIFOIL® R 2/2 
grids with continues carbon support.
Data collection, processing and refinement. The cryo-EM data for both SAuL22m_apo and SAuL22m_
ery structures were collected at the ESRF CM01 beamline41 using FEI Titan Krios (FEI) with K2 Summit (Gatan) 
direct electron detector, and Quantum LS imaging filter (Gatan) at a magnification of x130K, at defocus range of 
−0.5–1.0 nm and Pixel size of 1.067 A. The cryo-EM data for SAuL22m_apo structure were collected at 6.367 e−/
pix/s and 5.227 e−/A2/s. 40 frames per micrograph of 8 sec total length, 0.2 sec per frame and a total dose of 40 e−/
A2. 3542 movies were collected. From these micrographs 529,786 particles of SAuL22m_apo were selected for the 
2D classification, from them 145,897 particles were selected for 3D classification and 124,731 particles were used 
for the 3D refinement which gave a 3.58 Å resolution map for the whole 70 S ribosome and a resolution of 3.2 Å 
resolution map for the 50 S ribosomal LSU (Fig. S2, Table S1).
The cryo-EM data for SAuL22m_ery complex structure were collected at 5.231 e−/pix/s and 4.288 e−/A2/s. 
28 frames per micrograph of 7 sec with total length of 0.25 sec per frame and total dose of 30 e−/A2. 4161 movies 
were collected. From these micrographs 734,247 particles of SAuL22m_ery were selected for the 2D classifica-
tion, from them 426,250 particles were selected for 3D classification and 378,309 particles were used for the 3D 
Figure 6. VemP interaction with uL22. A view of VemP (green) with a surface representation of uL22 from E. 
coli (green), SA50S_WT (blue) both shows a similar structure while SAuL22m_apo (coral) and SAuL22m_ery 
complex (grey) reveals a wider path made possible by the shortening of the ß hairpin loop and the additional 
grove upon ery binding to SAuL22m_ery. Ery position is shown in red.
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refinement which gave a 2.42 Å resolution map for the whole 70 S ribosome and a resolution of 2.3 Å resolution 
map for the 50 S ribosomal LSU (Fig. S2, Table S1).
Data processing of SAuL22m_apo was performed using Relion 2.1. Whereas data of SAuL22m_ery were pro-
cessed using Relion 3.0-beta-242. The PDBID 5NGM was used as a starting model for the modeling of SAuL22m_
apo structure whereas the model of SAuL22m_apo was subsequently used as an initial model for SAuL22m_ery 
starting model. Manual refinement and modeling were done using Coot43 and refinement and validation were 
done using PHENIX44. Final validation and scoring were performed using MolProbity45–47.
figure generation and sequence alignment. All figures were generated with Chimera and 
ChimeraX48,49. Ribosome-erythromycin binding plot was generated using LigPlot+50. uL22 multiple sequence 
alignment was performed by ClustalW51 and presented by Jalview52.
Accession numbers. Atomic coordinates and structure factors for the reported EM structures have been 
deposited with the Protein Data bank under accession number 6S0X, 6S0Z, 6S12 and 6S13.
The EMDB accession number are 10076, 10077, 10078 and 10079.
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